DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing ¨C Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Ph3 Imlun vs Endo ER+ HER2- BC
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH) Read Moreabout Ph3 Imlun vs Endo ER+ HER2- BC
Phase: III
STAR Ph3 MRTX849 Cetux KRAS G12C CC
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010) Read Moreabout STAR Ph3 MRTX849 Cetux KRAS G12C CC
Phase: III
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing ¨C Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC
A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01) Read Moreabout STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC
Phase: I
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing ¨C Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
(FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Read Moreabout STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
Phase: III
STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202) Read Moreabout STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC
Phase: II
STAR Ph3 Ami Laz EGFR-mut NSCLC
A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002) Read Moreabout STAR Ph3 Ami Laz EGFR-mut NSCLC
Phase: III
STAR PH3 EGFRm stage2/3b NSCLC
A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001) Read Moreabout STAR PH3 EGFRm stage2/3b NSCLC
Phase: III
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC
Phase: III
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX) Read Moreabout STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
Phase: III
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing ¨C Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
Phase: II
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing ¨C Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
STAR PH3 Nirap Abira HRR mCSPC
A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002) Read Moreabout STAR PH3 Nirap Abira HRR mCSPC
Phase: III
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001 Read Moreabout STAR PH3 Abi+/-Capi mHSPC CAPItello-281
Phase: III
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing ¨C Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007) Read Moreabout STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
Phase: II
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing ¨C Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I